📊 OGEN Key Takeaways
Is Oragenics Inc. (OGEN) a Good Investment?
Oragenics is in severe financial distress with revenue collapsed 71% YoY to $37.7K while burning $2.3M annually in operating losses. Despite $6.1M in cash reserves and zero debt, the company demonstrates fundamental business model failure evidenced by zero gross profit and negative cash flows. Current cash runway provides only ~2.6 years before insolvency at present burn rate.
Oragenics is effectively pre-revenue with a collapsing top line and zero gross margin while incurring roughly $9–10M in annual operating losses. Although liquidity appears strong and the balance sheet is debt-free, the $4.4M cash balance implies a short runway relative to the burn rate and dependence on external financing. Without tangible commercial traction or improving operating leverage, fundamentals point to sustained losses and dilution risk.
Oragenics Inc. Key Strengths (OGEN)
- Zero debt and strong balance sheet with $6.1M cash reserves providing near-term solvency
- Excellent liquidity with 4.17x current ratio and no long-term obligations
- Current financial position allows time for potential strategic pivots or asset sales
- Debt-free balance sheet with low liabilities
- Strong liquidity (current and quick ratio 5.6x)
- Low capital intensity (minimal capex requirements)
OGEN Stock Risks: Oragenics Inc. Investment Risks
- Catastrophic revenue collapse of 71.4% YoY to near-zero levels ($37.7K)
- Massive operating losses with negative margins exceeding -5000% indicating fundamental business failure
- Negative operating cash flow of -$2.2M and free cash flow of -$2.3M demonstrates unsustainable burn rate
- Zero gross profit indicates inability to monetize core operations or generate scalable revenue
- Limited cash runway of approximately 2.6 years at current burn rate before capital exhaustion
- No insider activity in 90 days suggests management lacks confidence in turnaround prospects
- Severe operating and net losses with extreme negative margins
- De minimis revenue that declined 71% YoY and zero gross margin
- High likelihood of near-term capital raises and dilution due to limited runway
Key Metrics to Watch
- Operating cash flow trend and monthly cash burn rate
- Revenue growth and gross margin recovery as primary turnaround indicators
- Cash balance depletion timeline and liquidity adequacy
- Operating cash flow (burn rate)
- Revenue growth and commercialization progress
Oragenics Inc. (OGEN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.17x current ratio provides a solid financial cushion.
OGEN Profit Margin, ROE & Profitability Analysis
OGEN vs Healthcare Sector: How Oragenics Inc. Compares
How Oragenics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Oragenics Inc. Stock Overvalued? OGEN Valuation Analysis 2026
Based on fundamental analysis, Oragenics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Oragenics Inc. Balance Sheet: OGEN Debt, Cash & Liquidity
OGEN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Oragenics Inc.'s revenue has declined by 57% over the 5-year period, indicating business contraction. The most recent EPS of $-47.88 indicates the company is currently unprofitable.
OGEN Revenue Growth, EPS Growth & YoY Performance
OGEN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | $7.5K | -$2.0M | $-0.38 |
| Q2 2024 | $13.2K | -$2.3M | $-0.51 |
| Q1 2024 | $17.0K | -$2.5M | $-0.70 |
| Q3 2023 | $7.5K | -$2.0M | $-0.85 |
| Q2 2023 | $13.2K | -$2.8M | $-1.51 |
| Q1 2023 | $15.1K | -$2.8M | N/A |
| Q3 2022 | $86.0K | -$3.8M | N/A |
| Q2 2022 | $30.4K | -$3.8M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Oragenics Inc. Dividends, Buybacks & Capital Allocation
OGEN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Oragenics Inc. (CIK: 0001174940)
📋 Recent SEC Filings
❓ Frequently Asked Questions about OGEN
What is the AI rating for OGEN?
Oragenics Inc. (OGEN) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 81% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are OGEN's key strengths?
Claude: Zero debt and strong balance sheet with $6.1M cash reserves providing near-term solvency. Excellent liquidity with 4.17x current ratio and no long-term obligations. ChatGPT: Debt-free balance sheet with low liabilities. Strong liquidity (current and quick ratio 5.6x).
What are the risks of investing in OGEN?
Claude: Catastrophic revenue collapse of 71.4% YoY to near-zero levels ($37.7K). Massive operating losses with negative margins exceeding -5000% indicating fundamental business failure. ChatGPT: Severe operating and net losses with extreme negative margins. De minimis revenue that declined 71% YoY and zero gross margin.
What is OGEN's revenue and growth?
Oragenics Inc. reported revenue of $37.7K.
Does OGEN pay dividends?
Oragenics Inc. does not currently pay dividends.
Where can I find OGEN SEC filings?
Official SEC filings for Oragenics Inc. (CIK: 0001174940) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is OGEN's EPS?
Oragenics Inc. has a diluted EPS of $-0.51.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is OGEN's fundamental grade?
Based on our AI fundamental analysis in May 2026, Oragenics Inc. has a D grade with 81% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is OGEN stock overvalued or undervalued?
Valuation metrics for OGEN: ROE of -35.6% (sector avg: 15%), net margin of -5,846.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is OGEN's AI grade for 2026?
Our dual AI analysis gives Oragenics Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is OGEN's free cash flow?
Oragenics Inc.'s operating cash flow is $-2.2M, with capital expenditures of $127.5K. FCF margin is -6,183.2%.
How does OGEN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -5,846.1% (avg: 12%), ROE -35.6% (avg: 15%), current ratio 4.17 (avg: 2).